How concerned should we be about graphene's toxicity?

The potential toxicity of graphene and graphene oxide has been on people's minds lately. This is an area that has always received some attention, but recently there have been rumors and wild speculations about the adoption of graphene oxide and the risks involved.

Grapene toxicity poll results (August 2021)

Researchers have been studying the toxicity of graphene and graphene oxide for many years. While these materials have not yet been established as completely safe for use, there are quite a few research results that indicate that graphene can be relatively safe under the appropriate conditions.

Introducing: The CVD Graphene Market Report

Graphene-Info is proud to present our new market report, The CVD Graphene Market Report. This market report, brought to you by the world's leading graphene industry experts, is a comprehensive guide to CVD graphene materials, the current industry and market status, and the promising applications in optoelectronics, bio-sensors, thermal solutions and more.

Reading this report, you'll learn all about:

  • How does CVD graphene differ from other graphene types
  • CVD graphene properties
  • Possible applications for CVD graphene
  • Available materials on the market

The report also provides a list of prominent CVD graphene research activities, a list of all CVD graphene developers and their products, datasheets and brochures from over 10 different CVD graphene makers and more.

Research team examines graphene's effects on the lungs

Researchers from Empa and the Adolphe Merkle Institute (AMI) in Fribourg have conducted studies on a 3D lung model to examine the behavior of graphene and graphene-like materials once they have been inhaled.

AMI lung model imageThe lung model at Adolphe Merkle Institute (AMI)

Thanks to the 3-D lung model, the researchers have succeeded in simulating the actual conditions at the blood-air barrier and the impact of graphene on the lung tissue as realistically as possible – without any tests on animals or humans. It is a cell model representing the lung alveoli. Conventional in vitro tests work with cell cultures from just one cell type – the newly established lung model, on the other hand, bears three different cell types, which simulate the conditions inside the lung, namely alveolar epithelial cells and two kinds of immune cells – macrophages and dendritic cells.

Theragnostic Technologies receives grant to expand its graphene-based contrast agent platform to X-Ray CT procedures

In 2012, researchers from Stony Brook University established Theragnostic Technologies to develop a new efficient and cost-effective graphene-based MRI contrast agent. In 2015 Theragnostic launched the product, called ManGraDex, which needs several of years of clinical trials before it can be commercialized (the company aims for 2022 or 2023).

Theragnostic Technologies now announced that it has received a new SBIR phase-1 grant from the NIH to extend the ManGraDex platform for use in X-ray Computed Tomography (CT) imaging. The company will demonstrate the preclinical safety and efficacy of a novel graphene-enhanced CT contrast agent for imaging and monitoring in patients with renal failure or at risk of contrast induced nephropathy.

Nanomedical Diagnostics starts shipping its graphene-based sensors, explains its technology and business to Graphene-Info

San Diego-based Nanomedical Diagnostics, established in late 2013 to develop cutting-edge diagnostics equipment, recently started shipping its graphene-based sensors and the AGILE R100 system which allows for real-time detection of small molecules - with no lower size limit. Nanomedical's graphene-based sensors enable faster sample processing, greater accuracy, portability and cost savings.

Nanomedical Diagnostics Agile R100 photo

The company's CEO, Ross Bundy, was kind enough to explain the company's technology and business to us.